Clinical Trial Update: Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing denintuzumab mafodotin (SGN-CD19A) with RCHOP/RCHP vs RCHOP alone in diffuse large B-cell lymphoma and follicular lymphoma; trial termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• RCHOP (rituximab cyclophosphamide doxorubicin vincristine prednisone)
• denintuzumab mafodotin (denintuzumab mafodotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b | Phase 2 | Status: TERMINATED | Results posted: 2019-01-08